Publications by Amy Bullock

Publications by authors named "Amy Bullock"

J Clin Psychopharmacol

June 2024

Zuranolone is a new treatment for postpartum depression approved for a 14-day course and is being studied for how it transfers into breast milk.
In this study, lactating participants took a daily dose of 30 mg zuranolone, and the transfer was measured, revealing a relative infant dose (RID) of 0.357% after 5 days.
The findings suggest that the transfer of zuranolone into breast milk is low and stays well below the 10% threshold that is considered safe for breastfeeding.

Neuropsychopharmacology

January 2024

- Major depressive disorder (MDD) can significantly impact a person's ability to function and traditional antidepressant treatments take weeks to show effects; zuranolone is a new oral treatment that's been approved for postpartum depression and is being studied for MDD.
- The CORAL Study tested the effectiveness of zuranolone (50 mg) when combined with standard antidepressant therapy against a placebo in 425 adults with MDD, focusing on improvements in depression symptoms within the first three days.
- Results showed that patients taking zuranolone experienced a greater reduction in depression scores by Day 3 compared to those on placebo, with mild to moderate side effects being the most common, such as drowsiness and headaches.

Am J Psychiatry

September 2023

Postpartum depression (PPD) is a common issue affecting new mothers, and this study explored the effectiveness and safety of zuranolone as a treatment option over a 14-day period.
In a phase 3 trial with 196 participants, those taking zuranolone showed significant improvements in depression scores compared to those on a placebo, with benefits noted as early as day 3.
The treatment was well tolerated, with some side effects like somnolence and dizziness, but no serious risks such as loss of consciousness or increased suicidal thoughts were reported.

Hum Psychopharmacol

January 2022

This study aimed to assess the effectiveness of two doses of zuranolone (30 mg and 45 mg) in improving sleep in a phase advance insomnia model compared to a placebo.
In a double-blind crossover study, healthy adults were tested with three treatment periods and their sleep was measured using polysomnography and questionnaires.
Results showed that zuranolone significantly improved sleep metrics like sleep efficiency, wake after sleep onset, and total sleep time, with the drug being well tolerated overall, primarily causing mild side effects like headache and fatigue.

J Neurol Sci

February 2021

Parkinson's disease (PD) involves both motor and nonmotor symptoms, with tremor being difficult to treat, often not responsive to traditional dopamine therapy.
An open-label study tested zuranolone, a new oral treatment, on 14 PD patients over 7 days, focusing on reducing tremor symptoms measured by the MDS-UPDRS score.
Results showed a significant 40% improvement in tremor symptoms on Day 8 without serious side effects, with common mild adverse events including dizziness and sedation, suggesting zuranolone is a promising adjunct treatment for PD tremors.

Clin Pharmacokinet

January 2020

SAGE-217 is a new drug designed to modulate GABA receptors and was tested in phase I studies to evaluate its safety and how it behaves in the body (pharmacokinetics) after being taken orally.
In these studies, 108 healthy volunteers participated, where doses ranged from 0.25 to 66 mg for single doses and 15 to 35 mg for multiple daily doses over a week; the drug was mostly well tolerated with mild side effects.
The drug's pharmacokinetics showed it has a half-life of 16-23 hours, and after successful results, SAGE-217 is moving on to phase II studies for treating major depressive disorder